PubMed Health⌕ Search

Biomedical subjects

E García-Albea

Publications and source records attributed to E García-Albea.

At least 19 recordsLinked to original sources

Réplica.

Explore the source record for details and available documents.

Journal Article↗

Acoustic voice analysis in patients with essential tremor.

To quantify several acoustic features of the voice in patients with essential tremor (ET), 28 patients and 28 age- and sex-matched controls were studied. ET severity was assessed with the rating scale for tremor of Fahn, Tolosa, and Marín. The Computerized Speech Lab 4300 program (Kay Elemetrics) was used. Two-second samples of a sustained /a/ and a sentence were captured with a microphone and laryngograph equipment. Measures included fundamental frequency (F0), frequency perturbation (jitter, Koike algorithm), intensity perturbation (shimmer, Horii algorithm), and harmonic-to-noise ratio (H/N, Yumoto algorithm) of the vowel /a/, and the frequency and intensity variability of the sentence, phonational range, and dynamic range at the natural frequency, maximum phonational time, and s/z ratio. All subjects underwent indirect laryngoscopy and/or laryngeal fibroscopy. When compared with controls, ET patients showed higher jitter, lower H/N ratio (the last one only with laryngographic signal), of the vowel /a/, lower frequency variability in the microphonic signal, lower intensity variability in the laryngographic signal of the sentence, and significantly lower dynamic range at natural frequency of phonation. ET patients reported higher frequency of the presence of high voice intensity, tremor, and struggle. Several acoustic parameters were influenced by the severity of the disease, including shimmer, jitter, H/N ratio, frequency variability of the sentence, and s/z ratio, although neither of the acoustic analysis values or the phonetometric measurements were affected by the presence of voice tremor or by a successful pharmacological treatment of ET.

Aged↗

["El Informe Médico-Moral de la Penosissima y Rigorosa Enfermedad de la Epilepsi" (1763) by the Spaniard Pedro de Horta, the 1st American treatise on epilepsy].

In 1763 Pedro de Horta was requested by the prioress of the convent of San Gerónimo in Puebla de los Angeles to draw up a report to establish whether the epidemic of queer turns, violent shaking or epilepsy which affected the novices was caused by the Devil or was due to natural causes. Pedro de Horta, a doctor qualified in Mexico, methodically and thoroughly prepared an extensive monographic treatise on the illness which included all that was known at the time. The report showed the fierce debates provoked by the subject of epilepsy in the eighteenth century regarding whether it was of natural or supernatural origin. It also contained detailed accounts of the episodes, their causes and treatment. The Spaniard Pedro de Horta should be justly recognized as the first American epileptologist.

Adult↗

[Lafora disease and the two first cases of Alzheimer's disease published in Spain].

Gonzalo Rodríguez Lafora (Madrid 1886-1971) finished his neuropathological training in the Nervenklinik in Munich, together with Alzheimer. In 1910 he took over from Achúcarro in the mental hospital in Washington. In 1911, the year he described amylaceous bodies in myoclonic epilepsy, he had the chance to study a demented person, a former soldier in the American Civil War, who had progressive deterioration of his mental functions. Both clinical and anatomopathological studies were very detailed. He shared the discovery of granulovacuolar degeneration with Simchowitz. It was the eighth case in the literature. The second case (and third American patient) in 1914 was a demented person with goitre, also in Washington mental hospital, who was studied by means of a full series of psychological tests, and the autopsy findings were later described. These studies were not published in English, and perhaps for this reason were not as widely known as they should have been.

Alzheimer Disease↗

Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs.

To quantify several acoustic features of the voice in patients with Parkinson's disease (PD), 41 patients and 28 age and sex-matched controls were studied. PD severity was assessed with the Unified PD Rating Scale (UPDRS) and the Hoehn and Yahr staging. The Computerized Speech Lab 4300 program (Kay Elemetrics) was used. Two seconds of a sustained /a/ and a sentence were captured with a microphone and laryngograph equipment. Measures included fundamental frequency (F0), frequency perturbation (jitter), intensity perturbation (shimmer), and harmonic/noise ratio (H/N) of the vowel /a/, and frequency and intensity variability of a sentence, phonational range, dynamic range at the natural frequency, maximum phonational time and s/z ratio. All subjects underwent indirect laryngoscopy and/or laryngeal fibroscopy. When compared with controls, PD patients showed higher jitter, lower H/N ratio, lower frequency and intensity variability of the sentence, and lower phonational range and reported a higher frequency of the presence of low voice-intensity, monopitch, voice arrests, and struggle. These features seem to be unaffected by the duration and severity of the disease.

Aged↗

Serum and urinary manganese levels in patients with Parkinson's disease.

To elucidate the possible role of manganese in the risk of developing Parkinson's disease (PD), we compared serum levels of manganese, and 24-h manganese excretion by urine in 29 PD patients and in 27 matched controls. We also measured chromium and cobalt in the same samples. All these values did not differ significantly between the groups, they were not influenced by antiparkinsonian drugs, and they did not correlate with age, age at onset and duration of the PD, scores of the Unified PD Rating Scale or the Hoehn & Yahr staging in the PD group. These results might suggest that serum levels and urinary excretion of manganese are apparently unrelated to the risk of developing PD.

Activities of Daily Living↗

Serum levels of beta-carotene and other carotenoids in Parkinson's disease.

To elucidate the possible role of carotenoids in the risk for developing Parkinson's disease (PD), we compared serum levels of beta-carotene, alpha-carotene and lycopene, measured by high performance liquid chromatography, of 61 PD patients using their spouses as the control group. The serum levels of these 3 carotenoids did not differ significantly between PD patients and control groups. There was no influence of antiparkinsonian therapy on serum carotenoids levels, and these did not correlate with age, age at onset, scores of the Unified Parkinson Disease Rating Scale or the Hoehn and Yahr staging in the PD group. These results show that serum carotenoids concentrations are apparently unrelated to the risk for developing PD.

Aged↗